JP2008511328A - 抗アミロイドベータ抗体の製法 - Google Patents

抗アミロイドベータ抗体の製法 Download PDF

Info

Publication number
JP2008511328A
JP2008511328A JP2007530148A JP2007530148A JP2008511328A JP 2008511328 A JP2008511328 A JP 2008511328A JP 2007530148 A JP2007530148 A JP 2007530148A JP 2007530148 A JP2007530148 A JP 2007530148A JP 2008511328 A JP2008511328 A JP 2008511328A
Authority
JP
Japan
Prior art keywords
culture
medium
glutamine
per unit
unit volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007530148A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008511328A5 (cg-RX-API-DMAC10.html
Inventor
デニス・ドラピュー
イェン−トゥアン・ルアン
ジェイムズ・アール・マーサー
ワン・ウェンジ
ダニエル・ラスコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Research Ireland Ltd
Original Assignee
Wyeth Research Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Research Ireland Ltd filed Critical Wyeth Research Ireland Ltd
Publication of JP2008511328A publication Critical patent/JP2008511328A/ja
Publication of JP2008511328A5 publication Critical patent/JP2008511328A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/04—Plant cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2007530148A 2004-08-27 2005-08-26 抗アミロイドベータ抗体の製法 Pending JP2008511328A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60493604P 2004-08-27 2004-08-27
PCT/US2005/030364 WO2006026408A2 (en) 2004-08-27 2005-08-26 Production of anti-amyloid beta antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012033105A Division JP2012095671A (ja) 2004-08-27 2012-02-17 抗アミロイドベータ抗体の製法

Publications (2)

Publication Number Publication Date
JP2008511328A true JP2008511328A (ja) 2008-04-17
JP2008511328A5 JP2008511328A5 (cg-RX-API-DMAC10.html) 2008-10-16

Family

ID=35500647

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007530148A Pending JP2008511328A (ja) 2004-08-27 2005-08-26 抗アミロイドベータ抗体の製法
JP2012033105A Pending JP2012095671A (ja) 2004-08-27 2012-02-17 抗アミロイドベータ抗体の製法
JP2015075425A Pending JP2015133980A (ja) 2004-08-27 2015-04-01 抗アミロイドベータ抗体の製法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012033105A Pending JP2012095671A (ja) 2004-08-27 2012-02-17 抗アミロイドベータ抗体の製法
JP2015075425A Pending JP2015133980A (ja) 2004-08-27 2015-04-01 抗アミロイドベータ抗体の製法

Country Status (27)

Country Link
US (1) US7335491B2 (cg-RX-API-DMAC10.html)
EP (2) EP2348126A3 (cg-RX-API-DMAC10.html)
JP (3) JP2008511328A (cg-RX-API-DMAC10.html)
KR (1) KR100998857B1 (cg-RX-API-DMAC10.html)
CN (1) CN101048512B (cg-RX-API-DMAC10.html)
AR (1) AR050471A1 (cg-RX-API-DMAC10.html)
AU (1) AU2005280090A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0514680A (cg-RX-API-DMAC10.html)
CA (1) CA2578137C (cg-RX-API-DMAC10.html)
CR (1) CR8996A (cg-RX-API-DMAC10.html)
EC (1) ECSP077351A (cg-RX-API-DMAC10.html)
EG (1) EG25848A (cg-RX-API-DMAC10.html)
ES (1) ES2599103T3 (cg-RX-API-DMAC10.html)
HN (1) HN2005000486A (cg-RX-API-DMAC10.html)
IL (1) IL181587A (cg-RX-API-DMAC10.html)
MX (1) MX2007002382A (cg-RX-API-DMAC10.html)
MY (1) MY146097A (cg-RX-API-DMAC10.html)
NO (1) NO20071571L (cg-RX-API-DMAC10.html)
NZ (1) NZ591233A (cg-RX-API-DMAC10.html)
PE (2) PE20100147A1 (cg-RX-API-DMAC10.html)
RU (1) RU2418858C2 (cg-RX-API-DMAC10.html)
SG (1) SG155250A1 (cg-RX-API-DMAC10.html)
SV (1) SV2006002212A (cg-RX-API-DMAC10.html)
TW (1) TWI374935B (cg-RX-API-DMAC10.html)
UA (1) UA89644C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006026408A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200702487B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023513830A (ja) * 2020-02-18 2023-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 哺乳動物細胞培養プロセス

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
DK2041270T3 (da) * 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
RU2498999C2 (ru) * 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
MX2009004519A (es) * 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
MX2009004974A (es) * 2006-11-08 2009-05-20 Wyeth Corp Medios diseñado racionalmente para cultivo celular.
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) * 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
CA2679941C (en) * 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2008136398A1 (ja) 2007-04-26 2008-11-13 Chugai Seiyaku Kabushiki Kaisha 高濃度アミノ酸含有培地を用いた細胞の培養方法
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
HRP20150086T1 (xx) * 2007-06-12 2015-02-27 Ac Immune S.A. Humanizirana antitijela za beta amiloid
PL2238166T3 (pl) * 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
AU2009236187B2 (en) * 2008-04-17 2012-08-02 Wyeth Llc Methods for enhanced production of bone morphogenetic proteins
AU2009290563A1 (en) 2008-09-15 2010-03-18 Genentech, Inc. Compositions and methods for regulating cell osmolarity
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
US8470552B2 (en) * 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
AU2011246503B2 (en) 2010-04-26 2013-09-26 Novartis Ag Improved cell culture medium
LT2563906T (lt) 2010-04-26 2018-02-26 Novartis Ag Cho ląstelių kultivavimo būdas
CN102858953B (zh) 2010-04-26 2015-09-09 诺瓦提斯公司 改进的细胞培养基
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
SI2726600T1 (sl) * 2011-07-01 2017-07-31 Amgen Inc. Sesalska celična kultura
FI20115704A7 (fi) 2011-07-01 2013-01-02 Teknologian Tutkimuskeskus Vtt Oy Vierasproteiinien tuoton parantaminen
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
PL3812453T3 (pl) 2013-10-11 2026-07-13 Regeneron Pharmaceuticals, Inc. Hodowla komórkowa zoptymalizowana metabolicznie
DE102017203908B3 (de) * 2017-03-09 2018-05-30 Evonik Technochemie Gmbh Kulturmedium, umfassend Oligopeptide
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
WO2018229274A1 (en) * 2017-06-16 2018-12-20 Katholieke Universiteit Leuven Cell culture media for differentiation of stem cells into hepatocytes
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
IL279782B2 (en) * 2018-07-03 2026-05-01 Bristol Myers Squibb Co Methods for producing recombinant proteins
IL309560B2 (en) 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501660A (ja) * 1988-09-23 1992-03-26 カイロン　コーポレーション 増強された細胞増殖、培養寿命および生産物発現のための細胞培養培地
JPH06502551A (ja) * 1991-08-30 1994-03-24 アルスイス・ホールディングス・アクチェンゲゼルシャフト 付着性動物細胞の増殖のための細胞培養方法および培地
JP2002501374A (ja) * 1997-04-07 2002-01-15 ナショナル・ユニバーシティ・オブ・シンガポール 強化されたタンパク産生のための細胞培養培地
WO2002046237A2 (en) * 2000-12-06 2002-06-13 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
WO2002101019A2 (en) * 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
WO2003077858A2 (en) * 2002-03-12 2003-09-25 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20040048368A1 (en) * 1994-03-10 2004-03-11 Genentech, Inc. Polypeptide production in animal cell culture

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8516415D0 (en) * 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US5672502A (en) * 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) * 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
JPH059735A (ja) * 1991-07-09 1993-01-19 Kobe Steel Ltd ダイヤモンドの気相合成方法
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
WO1997041895A2 (en) * 1996-05-08 1997-11-13 F. Hoffmann-La Roche Ag TREATMENT OF ASTHMA WITH TNFR-Ig
WO1998041611A1 (en) * 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6537782B1 (en) * 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
EP1150688A4 (en) 1998-10-19 2004-06-16 Yeda Res & Dev TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY NEGATIVE REGULATION OF THE AUTO-IMMUNE RESPONSE TO AUTOANTIGENS
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
AU2002258808A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
ATE409047T1 (de) 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501660A (ja) * 1988-09-23 1992-03-26 カイロン　コーポレーション 増強された細胞増殖、培養寿命および生産物発現のための細胞培養培地
JPH06502551A (ja) * 1991-08-30 1994-03-24 アルスイス・ホールディングス・アクチェンゲゼルシャフト 付着性動物細胞の増殖のための細胞培養方法および培地
US20040048368A1 (en) * 1994-03-10 2004-03-11 Genentech, Inc. Polypeptide production in animal cell culture
JP2002501374A (ja) * 1997-04-07 2002-01-15 ナショナル・ユニバーシティ・オブ・シンガポール 強化されたタンパク産生のための細胞培養培地
WO2002046237A2 (en) * 2000-12-06 2002-06-13 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
WO2002101019A2 (en) * 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
WO2003077858A2 (en) * 2002-03-12 2003-09-25 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6011013805; Ｃｙｔｏｔｅｃｈｎｏｌｏｇｙ，　１９９４，　Ｖｏｌ．１６，　ｐ．３７-４２ *
JPN6012040256; Ｊｏｕｒｎａｌ　ｏｆ　Ｂｉｏｔｅｃｈｎｏｌｏｇｙ ｖｏｌ．１５, 1990, ｐｐ．１１３-１２８
JPN6012040257; ＢＩＯＴＥＣＨＮＯＬＯＧＹ　ＡＮＤ　ＢＩＯＥＮＧＩＮＥＥＲＩＮＧ ｖｏｌ．６３　ｎｏ．５, 1999, ｐｐ．５７３-５８２
JPN6012040258; ＢＩＯＴＥＣＨＮＯＬＯＧＹ　ＡＮＤ　ＢＩＯＥＮＧＩＮＥＥＲＩＮＧ ｖｏｌ．８５　ｎｏ．２, 2004, ｐｐ．１７７-１８４

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023513830A (ja) * 2020-02-18 2023-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 哺乳動物細胞培養プロセス
JP7551760B2 (ja) 2020-02-18 2024-09-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 哺乳動物細胞培養プロセス
JP2024170527A (ja) * 2020-02-18 2024-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 哺乳動物細胞培養プロセス

Also Published As

Publication number Publication date
EP2348126A3 (en) 2011-10-12
NZ591233A (en) 2012-09-28
MX2007002382A (es) 2007-06-15
AU2005280090A1 (en) 2006-03-09
CA2578137C (en) 2010-11-09
EG25848A (en) 2012-09-10
MY146097A (en) 2012-06-29
HN2005000486A (es) 2010-03-29
SG155250A1 (en) 2009-09-30
KR20070073737A (ko) 2007-07-10
EP2348126A2 (en) 2011-07-27
AR050471A1 (es) 2006-10-25
WO2006026408A2 (en) 2006-03-09
IL181587A0 (en) 2007-07-04
WO2006026408A3 (en) 2006-05-04
TWI374935B (en) 2012-10-21
ECSP077351A (es) 2008-03-26
JP2012095671A (ja) 2012-05-24
RU2418858C2 (ru) 2011-05-20
TW200615379A (en) 2006-05-16
US7335491B2 (en) 2008-02-26
UA89644C2 (ru) 2010-02-25
CR8996A (es) 2007-10-10
SV2006002212A (es) 2006-06-26
JP2015133980A (ja) 2015-07-27
KR100998857B1 (ko) 2010-12-08
CA2578137A1 (en) 2006-03-09
RU2007108718A (ru) 2008-10-10
CN101048512B (zh) 2013-04-17
EP1781803A2 (en) 2007-05-09
US20060160180A1 (en) 2006-07-20
ZA200702487B (en) 2011-10-26
BRPI0514680A (pt) 2008-06-17
NO20071571L (no) 2007-05-23
ES2599103T3 (es) 2017-01-31
PE20100147A1 (es) 2010-03-02
PE20060715A1 (es) 2006-08-15
EP1781803B1 (en) 2016-08-24
CN101048512A (zh) 2007-10-03
IL181587A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
JP5921910B2 (ja) ＴＮＦＲ−Ｉｇ融合タンパク質の製法
JP4864892B2 (ja) ポリペプチドの製造
CA2578137C (en) Production of .alpha.-abeta
AU2012200353B2 (en) PRODUCTION OF a-ABeta
HK1180013B (en) Production of polypeptides
HK1181073A (en) Production of tnfr-ig fusion protein
HK1180013A (en) Production of polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110613

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110714

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110812

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110915

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120217

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120508

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120530

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130903

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131003

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131101

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131107

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120